IRADIMED Future Growth
Future criteria checks 2/6
IRADIMED is forecast to grow earnings and revenue by 14.3% and 13.3% per annum respectively while EPS is expected to grow by 13.4% per annum.
Key information
14.3%
Earnings growth rate
13.4%
EPS growth rate
Medical Equipment earnings growth | 17.5% |
Revenue growth rate | 13.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 02 Aug 2024 |
Recent future growth updates
Recent updates
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Aug 08If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
Feb 23Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
Feb 07Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
Nov 06Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Oct 13At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
Feb 05Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y
Oct 10IRadimed: Record Revenue Could Translate To Share Price Appreciation
Aug 23Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching
Aug 17iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M
Jul 29IRadimed: Reduce Equity Beta With Upside Capture
Jul 18IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively
Jul 13At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?
Feb 05Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital
Jan 12Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture
Jul 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 99 | 27 | N/A | N/A | 1 |
12/31/2025 | 80 | 20 | N/A | N/A | 2 |
12/31/2024 | 73 | 18 | N/A | N/A | 2 |
6/30/2024 | 69 | 19 | 13 | 16 | N/A |
3/31/2024 | 68 | 18 | 11 | 13 | N/A |
12/31/2023 | 66 | 17 | 5 | 13 | N/A |
9/30/2023 | 63 | 16 | 5 | 13 | N/A |
6/30/2023 | 60 | 15 | 7 | 15 | N/A |
3/31/2023 | 56 | 14 | 5 | 13 | N/A |
12/31/2022 | 53 | 13 | 8 | 10 | N/A |
9/30/2022 | 50 | 13 | 9 | 10 | N/A |
6/30/2022 | 48 | 12 | 9 | 10 | N/A |
3/31/2022 | 45 | 10 | 11 | 12 | N/A |
12/31/2021 | 42 | 9 | 11 | 11 | N/A |
9/30/2021 | 38 | 6 | 10 | 10 | N/A |
6/30/2021 | 35 | 5 | 8 | 8 | N/A |
3/31/2021 | 32 | 1 | 5 | 6 | N/A |
12/31/2020 | 32 | 1 | 5 | 6 | N/A |
9/30/2020 | 34 | 4 | 7 | 7 | N/A |
6/30/2020 | 36 | 5 | 8 | 9 | N/A |
3/31/2020 | 39 | 10 | 10 | 11 | N/A |
12/31/2019 | 39 | 10 | 10 | 10 | N/A |
9/30/2019 | 36 | 8 | 9 | 10 | N/A |
6/30/2019 | 34 | 8 | 7 | 7 | N/A |
3/31/2019 | 32 | 7 | 6 | 6 | N/A |
12/31/2018 | 30 | 6 | 7 | 7 | N/A |
9/30/2018 | 29 | 5 | 5 | 5 | N/A |
6/30/2018 | 27 | 3 | 6 | 6 | N/A |
3/31/2018 | 25 | 2 | N/A | 5 | N/A |
12/31/2017 | 23 | 0 | N/A | 3 | N/A |
9/30/2017 | 22 | 1 | N/A | 4 | N/A |
6/30/2017 | 24 | 3 | N/A | 6 | N/A |
3/31/2017 | 29 | 5 | N/A | 7 | N/A |
12/31/2016 | 32 | 7 | N/A | 9 | N/A |
9/30/2016 | 35 | 8 | N/A | 10 | N/A |
6/30/2016 | 35 | 9 | N/A | 9 | N/A |
3/31/2016 | 33 | 8 | N/A | 9 | N/A |
12/31/2015 | 31 | 8 | N/A | 8 | N/A |
9/30/2015 | 26 | 5 | N/A | 4 | N/A |
6/30/2015 | 22 | 4 | N/A | 3 | N/A |
3/31/2015 | 19 | 3 | N/A | 3 | N/A |
12/31/2014 | 15 | 2 | N/A | 3 | N/A |
9/30/2014 | 15 | 2 | N/A | 4 | N/A |
6/30/2014 | 14 | 2 | N/A | 3 | N/A |
3/31/2014 | 12 | 2 | N/A | 2 | N/A |
12/31/2013 | 11 | 2 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRMD's forecast earnings growth (14.3% per year) is above the savings rate (2.5%).
Earnings vs Market: IRMD's earnings (14.3% per year) are forecast to grow slower than the US market (15.3% per year).
High Growth Earnings: IRMD's earnings are forecast to grow, but not significantly.
Revenue vs Market: IRMD's revenue (13.3% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: IRMD's revenue (13.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IRMD's Return on Equity is forecast to be high in 3 years time